← Eichor
Condition: Lesion Femoral Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Lesion Femoral

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

STAR-PAK Study: Evaluating the Safety and Efficacy of PAK® (Paclitaxel Coated Balloon) in Treating Atherosclerotic Femor
NA · 3 location(s) · Balton Sp.zo.o. · NCT06734221
Nanochon Chondrograft First in Human (FIH) Early Feasibility Study (EFS) - Canada
NA · 2 location(s) · Nanochon, Inc. · NCT07249489
Bypass Versus Endovascular Procedure in Long Lesions of the Superficial Femoral Artery in the Claudicant
NA · 16 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05216731
CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common
Phase N/A · 2 location(s) · Yale University · NCT05145478
Early Feasibility Study of Cartilage Defect Repair
NA · 1 location(s) · Cytex Therapeutics, Inc. · NCT06823089
BioPoly® Partial Resurfacing Knee Implant IDE
NA · 4 location(s) · BioPoly LLC · NCT06915363
Prospective, Multicenter, Single-Arm Observational Study to Confirm the Safety and Clinical Performance of the Oscar Per
Phase N/A · 16 location(s) · Biotronik AG · NCT06758921
Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study
Phase N/A · 12 location(s) · Hospices Civils de Lyon · NCT04170634
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.